Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
Masimo (MASI) Boosts Its Product Suite With Latest Release
by Zacks Equity Research
Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.
MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on
by Debanjana Dey
Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.
Masimo (MASI) Reports Study Findings Backing the SedLine
by Zacks Equity Research
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
by Zacks Equity Research
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
by Zacks Equity Research
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
Masimo (MASI) Down 4.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome
by Zacks Equity Research
Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Masimo (MASI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 2.27% and 0.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Masimo (MASI) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.
4 Critical Care Device Stocks to Deflect the COVID-19 Curveball
by Debanjana Dey
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator
by Zacks Equity Research
Ecolab's (ECL) smart tool is expected to bridge the widening gap between freshwater supply and demand via efficient water management.
Masimo (MASI) Down 10.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD
by Zacks Equity Research
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
Masimo's (MASI) EMMA Favored by New Study for Children
by Zacks Equity Research
The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization
by Urmimala Biswas
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
Masimo's (MASI) Rad-G with Temperature Receives CE Marking
by Zacks Equity Research
Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
Is a Surprise Coming for Masimo Corporation (MASI) This Earnings Season?
by Zacks Equity Research
Masimo Corporation (MASI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN
by Zacks Equity Research
Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.
Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry
by Zacks Equity Research
Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.
Why the Earnings Surprise Streak Could Continue for Masimo (MASI)
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
by Zacks Equity Research
Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.